Detail akcie Esperion Therap online

Business Summary: Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Esperion Therapeutics Inc revenues increased 23% to $80.1M. Net loss decreased 38% to $25.2M. Revenues reflect Product sales, net increase of 24% to $43.4M, Collaboration revenue increase of 22% to $36.7M. Lower net loss reflects Researching, developing and commericializing segment loss decrease of 70% to $6.6M.